MCID: CRC006
MIFTS: 61

Carcinoid Syndrome

Categories: Cancer diseases, Endocrine diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Carcinoid Syndrome

MalaCards integrated aliases for Carcinoid Syndrome:

Name: Carcinoid Syndrome 53
Carcinoid Tumor 53 29 73
Carcinoid Tumor No Icd-O Subtype 73
Malignant Carcinoid Syndrome 73
Carcinoid Tumor Syndrome 53
Carcinoid Tumors 43

Classifications:



Summaries for Carcinoid Syndrome

NIH Rare Diseases : 53 Carcinoid syndrome refers to a group of symptoms that are associated with carcinoid tumors (rare, slow-growing tumors that occur most frequently in the gastroinestinal tract or lungs). Affected people may experience skin flushing, abdominal pain, diarrhea, difficulty breathing, rapid heart rate, low blood pressure, skin lesions on the face (telangiectasias), and wheezing. In later stages, carcinoid syndrome may damage the heart valves, resulting in symptoms of congestive heart failure. The condition occurs when the carcinoid tumor secretes serotonin or other chemicals into the bloodstream. Only 10% of people with carcinoid tumors develop carcinoid syndrome; most have advanced stage carcinoid tumors that have spread to the liver. Treatment generally involves addressing the underlying carcinoid tumor and medications to alleviate symptoms.

MalaCards based summary : Carcinoid Syndrome, also known as carcinoid tumor, is related to carcinoid tumors, intestinal and pulmonary blastoma. An important gene associated with Carcinoid Syndrome is CHGA (Chromogranin A), and among its related pathways/superpathways are Neuroscience and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Afinitor and Levoleucovorin have been mentioned in the context of this disorder. Affiliated tissues include lung, heart and liver, and related phenotypes are nausea and vomiting and myopathy

MedlinePlus : 43 Carcinoid tumors are rare, slow-growing cancers. They usually start in the lining of the digestive tract or in the lungs. They grow slowly and don't produce symptoms in the early stages. As a result, the average age of people diagnosed with digestive or lung carcinoids is about 60. In later stages the tumors sometimes produce hormones that can cause carcinoid syndrome. The syndrome causes flushing of the face and upper chest, diarrhea, and trouble breathing. Surgery is the main treatment for carcinoid tumors. If they haven't spread to other parts of the body, surgery can cure the cancer.

Wikipedia : 76 Carcinoid syndrome is a paraneoplastic syndrome comprising the signs and symptoms that occur secondary... more...

Related Diseases for Carcinoid Syndrome

Diseases related to Carcinoid Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 415)
# Related Disease Score Top Affiliating Genes
1 carcinoid tumors, intestinal 32.3 CHGA ENO2 MEN1 SST SYP
2 pulmonary blastoma 32.1 CHGA SYP
3 serotonin syndrome 31.3 CHGA GHRH HTR3A IFNA2 MEN1 PYY
4 goblet cell carcinoid 30.8 CHGA ENO2
5 horseshoe kidney 30.5 CHGA ENO2 SYP
6 adenoma 30.3 IGF1 MEN1 SST
7 small cell carcinoma 30.1 CALCA CHGA ENO2 SYP
8 paraganglioma 30.0 CHGA ENO2 SST SYP
9 sclerosing hemangioma 29.9 CHGA SYP
10 glomus tumor 29.9 ENO2 SYP
11 thyroid cancer 29.8 CALCA CHGA SST VEGFA
12 multiple endocrine neoplasia 29.7 CALCA CHGA MEN1
13 somatostatinoma 29.6 CALCA CHGA ENO2 SST
14 thyroid carcinoma, familial medullary 29.6 CALCA CHGA ENO2 MEN1 SST
15 vipoma 29.6 CHGA NTS SST
16 gastrinoma 29.6 CHGA MEN1 SST
17 parathyroid adenoma 29.5 CALCA CHGA MEN1
18 insulinoma 29.5 CHGA MEN1 SST
19 small cell cancer of the lung 29.5 CALCA CHGA ENO2 SST SYP
20 primary hyperparathyroidism 29.5 CALCA CHGA MEN1
21 hyperparathyroidism 29.5 CALCA CHGA MEN1
22 hemangioma 29.5 CHGA ENO2 SYP VEGFA
23 acromegaly 29.5 GHRH IGF1 MEN1 SST
24 pituitary adenoma, prolactin-secreting 29.5 IGF1 MEN1 SST
25 ectopic cushing syndrome 29.4 MEN1 SST SYP
26 ependymoma 29.4 ENO2 MEN1 SYP
27 islet cell tumor 29.4 CALCA CHGA MEN1 SST
28 constipation 29.4 CALCA HTR3A NPY NTS PYY SST
29 zollinger-ellison syndrome 29.3 CHGA GHRH MEN1 NTS SST
30 neuroendocrine tumor 29.3 CALCA CHGA ENO2 MEN1 NTS SST
31 von hippel-lindau syndrome 29.1 CHGA MEN1 NPY VEGFA
32 multiple endocrine neoplasia, type i 29.1 CHGA GHRH MEN1 SST SYP
33 gastrointestinal stromal tumor 29.0 CHGA ENO2 MEN1 SYP VEGFA
34 ewing sarcoma 29.0 CHGA ENO2 IGF1 NPY SYP VEGFA
35 pheochromocytoma 28.9 CALCA CHGA ENO2 MEN1 NPY SST
36 appendix carcinoid tumor 12.4
37 neurofibromatosis-pheochromocytoma-duodenal carcinoid syndrome 12.2
38 carcinoid tumor childhood 12.1
39 diffuse idiopathic pulmonary neuroendocrine cell hyperplasia 11.5
40 pleuropulmonary blastoma 11.1
41 pulmonary valve stenosis 11.1
42 insulinomatosis and diabetes mellitus 10.3 CHGA SST
43 tsh producing pituitary tumor 10.3 GHRH SST
44 heart disease 10.3
45 neuroaxonal dystrophy 10.3 ENO2 IGF1
46 orbital plasma cell granuloma 10.3 IFNA2 SST
47 isolated growth hormone deficiency, type ib 10.3 GHRH IGF1
48 wdha syndrome 10.3 CALCA SST
49 anterior cranial fossa meningioma 10.3 CHGA SYP
50 pleomorphic xanthoastrocytoma 10.3 CHGA SYP

Graphical network of the top 20 diseases related to Carcinoid Syndrome:



Diseases related to Carcinoid Syndrome

Symptoms & Phenotypes for Carcinoid Syndrome

Human phenotypes related to Carcinoid Syndrome:

32 (show all 25)
# Description HPO Frequency HPO Source Accession
1 nausea and vomiting 32 occasional (7.5%) HP:0002017
2 myopathy 32 very rare (1%) HP:0003198
3 asthma 32 occasional (7.5%) HP:0002099
4 episodic abdominal pain 32 frequent (33%) HP:0002574
5 tricuspid regurgitation 32 occasional (7.5%) HP:0005180
6 night sweats 32 frequent (33%) HP:0030166
7 paraganglioma 32 very rare (1%) HP:0002668
8 heart murmur 32 occasional (7.5%) HP:0030148
9 rhinorrhea 32 occasional (7.5%) HP:0031417
10 palpitations 32 occasional (7.5%) HP:0001962
11 right ventricular failure 32 occasional (7.5%) HP:0001708
12 chronic noninfectious lymphadenopathy 32 occasional (7.5%) HP:0002730
13 hepatic necrosis 32 very rare (1%) HP:0002605
14 erythematous plaque 32 frequent (33%) HP:0025474
15 facial telangiectasia 32 occasional (7.5%) HP:0007380
16 intestinal carcinoid 32 frequent (33%) HP:0006723
17 lack of bowel sounds 32 very rare (1%) HP:0030145
18 increased serum serotonin 32 occasional (7.5%) HP:0003144
19 protracted diarrhea 32 frequent (33%) HP:0004385
20 bronchospasm 32 occasional (7.5%) HP:0025428
21 small intestine carcinoid 32 frequent (33%) HP:0006722
22 abnormal b-type natriuretic peptide level 32 occasional (7.5%) HP:0031138
23 atypical pulmonary carcinoid tumor 32 very rare (1%) HP:0030446
24 epiphora 32 occasional (7.5%) HP:0009926
25 elevated hepatic transaminase 32 occasional (7.5%) HP:0002910

MGI Mouse Phenotypes related to Carcinoid Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.9 CHGA ENO2 GHRH HTR3A IGF1 MEN1
2 homeostasis/metabolism MP:0005376 9.65 CHGA GHRH HTR3A IGF1 MEN1 NPY
3 nervous system MP:0003631 9.4 CHGA ENO2 GHRH HTR3A IGF1 MEN1

Drugs & Therapeutics for Carcinoid Syndrome

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Afinitor 18 49 EVEROLIMUS Novartis March 2009

Drugs for Carcinoid Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 139)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 1 68538-85-2
2
Fluorouracil Approved Phase 2, Phase 3,Phase 1 51-21-8 3385
3
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
4
leucovorin Approved Phase 2, Phase 3,Phase 3,Phase 1 58-05-9 6006 143
5
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 1 61825-94-3 43805 6857599 5310940 9887054
6
Somatostatin Approved, Investigational Phase 3,Phase 2,Phase 1 51110-01-1, 38916-34-6 53481605
7 lanreotide Approved Phase 3,Phase 2 108736-35-2
8
Octreotide Approved, Investigational Phase 3,Phase 2,Phase 1 83150-76-9 383414 6400441
9
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
10
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
11
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
12 tannic acid Approved Phase 3
13
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
14
Methylene blue Approved, Investigational Phase 3 61-73-4
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
16 Pancreatic Polypeptide Investigational Phase 2, Phase 3,Phase 1,Not Applicable 59763-91-6
17 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
18 Vitamin B9 Phase 2, Phase 3
19 Immunologic Factors Phase 2, Phase 3,Phase 3,Phase 1
20 Immunosuppressive Agents Phase 2, Phase 3,Phase 3,Phase 1
21 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
22 Folate Phase 2, Phase 3
23 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
24 Antimetabolites Phase 2, Phase 3,Phase 1
25 Angiopeptin Phase 3,Phase 2
26 Hormones Phase 3,Phase 2,Phase 1
27 Hormone Antagonists Phase 3,Phase 2,Phase 1
28 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
29 Pharmaceutical Solutions Phase 3,Phase 2
30 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
31 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
32 Antifungal Agents Phase 3,Phase 2,Phase 1
33 Anti-Infective Agents Phase 3,Phase 2,Phase 1
34 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
35 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
36
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
37
Pasireotide Approved Phase 2 396091-73-9 9941444
38
Peginterferon alfa-2b Approved Phase 2 99210-65-8, 215647-85-1
39
Irinotecan Approved, Investigational Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
40
Pancrelipase Approved, Investigational Phase 2 53608-75-6
41
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
42
Streptozocin Approved, Investigational Phase 2 18883-66-4 29327
43
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
44
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
45
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
46
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
47
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
48
Hydroxyurea Approved Phase 2 127-07-1 3657
49
Lenograstim Approved, Investigational Phase 2 135968-09-1
50
Floxuridine Approved Phase 2 50-91-9 5790

Interventional clinical trials:

(show top 50) (show all 71)
# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
2 An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome Completed NCT00774930 Phase 3 Lanreotide;Placebo
3 Telotristat Etiprate for Carcinoid Syndrome Therapy Completed NCT02063659 Phase 3 Telotristat etiprate;Placebo
4 TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome) Completed NCT01677910 Phase 3 Telotristat etiprate;Placebo-matching telotristat etiprate
5 Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor Completed NCT00412061 Phase 3 Octreotide;Placebo;Everolimus
6 Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) Completed NCT01626378 Phase 3 TRx0237;Placebo
7 Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery Recruiting NCT03375320 Phase 3 Cabozantinib S-malate
8 Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms Active, not recruiting NCT02026063 Phase 3 Telotristat etiprate tablets (250 mg)
9 Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome Terminated NCT00092287 Phase 3 lanreotide Autogel (somatostatin analogue);Sandostatin long acting release (LAR) Depot (somatostatin analogue)
10 A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors Unknown status NCT01731925 Phase 2 Lanreotide;Placebo (for sunitinib);Sunitinib
11 Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Completed NCT01104415 Phase 2 Low Dose LX1606 - Day 1 (start);Mid-low dose LX1606 - Day 15 (start);Mid-high dose LX1606 - Day 29 (start);High dose LX1606 - Day 43 (start)
12 Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy Completed NCT00853047 Phase 2 Telotristat etiprate;Octreotide LAR Depot;Placebo
13 Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors Completed NCT00088595 Phase 2 Pasireotide (SOM230)
14 Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) Completed NCT02299089 Phase 2 octreotide FluidCrystal® injection depot
15 Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors Completed NCT00002470 Phase 2 fluorouracil
16 Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors Completed NCT00055809 Phase 2
17 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
18 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
19 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
20 Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma Completed NCT00093782 Phase 2 temsirolimus
21 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
22 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2 thalidomide
23 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
24 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
25 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
26 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
27 Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer Completed NCT00019474 Phase 2 fluorouracil;hydroxyurea
28 Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction Completed NCT00004911 Phase 1, Phase 2
29 Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction Completed NCT00004910 Phase 1, Phase 2
30 Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer Completed NCT00005049 Phase 2 carboplatin;cisplatin;floxuridine
31 Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs Recruiting NCT03722511 Phase 2
32 Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors Active, not recruiting NCT01782443 Phase 2 Ziv-aflibercept
33 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Active, not recruiting NCT02259725 Phase 2 regorafenib
34 Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors Active, not recruiting NCT01841736 Phase 2 Pazopanib Hydrochloride
35 AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With Metastatic Well Differentiated Neuroendocrine Neoplasm Not yet recruiting NCT03453489 Phase 2 Telotristat Etiprate
36 Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome Terminated NCT00884715 Phase 1, Phase 2 Octreotide
37 Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome Terminated NCT01018953 Phase 2 BIM 23A760
38 P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome Terminated NCT01886287 Phase 2 Octreotide LAR
39 Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Terminated NCT00084461 Phase 2 romidepsin
40 Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer Terminated NCT00903396 Phase 2 palonosetron hydrochloride
41 Study of Panitumumab in the Treatment of Carcinoid Syndrome Withdrawn NCT01172717 Phase 2 Panitumumab
42 Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2 octreotide acetate;vatalanib
43 An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males Completed NCT01932528 Phase 1 500 mg [14C]-LX1606
44 Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Completed NCT01548482 Phase 1 Temsirolimus
45 Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1 Everolimus;Octreotide Acetate
46 Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors Completed NCT01155258 Phase 1 temsirolimus;vinorelbine ditartrate
47 Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features Completed NCT01048892 Phase 1 cyclophosphamide
48 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Completed NCT00655655 Phase 1 everolimus;vatalanib
49 Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer Completed NCT00654160 Phase 1 fluorouracil;irinotecan hydrochloride;leucovorin calcium
50 Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Completed NCT00397384 Phase 1 cetuximab;erlotinib hydrochloride

Search NIH Clinical Center for Carcinoid Syndrome

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Carcinoid Syndrome

Genetic tests related to Carcinoid Syndrome:

# Genetic test Affiliating Genes
1 Carcinoid Tumor 29

Anatomical Context for Carcinoid Syndrome

MalaCards organs/tissues related to Carcinoid Syndrome:

41
Lung, Heart, Liver, Skin, Ovary, Kidney, Appendix

Publications for Carcinoid Syndrome

Articles related to Carcinoid Syndrome:

(show top 50) (show all 1736)
# Title Authors Year
1
Cost-effectiveness analysis of telotristat ethyl for treatment of carcinoid syndrome diarrhea inadequately controlled with somatostatin analogs. ( 28959913 )
2018
2
Developments in the treatment of carcinoid syndrome - impact of telotristat. ( 29503551 )
2018
3
Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial. ( 29330194 )
2018
4
LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAA8VE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY. ( 29547049 )
2018
5
Carcinoid-syndrome: recent advances, current status and controversies. ( 29120923 )
2018
6
Telotristat Ethyl for Patients With Carcinoid Syndrome Associated With Chest Pain and Hypertension. ( 29232344 )
2018
7
A case of a primary lung cancer comprised of adenocarcinoma and atypical carcinoid tumor with both components harboring BRAF p.V600E mutation. ( 29248665 )
2018
8
The management of refractory carcinoid syndrome: challenges and opportunities ahead. ( 29039712 )
2018
9
Diagnostic Dilemma: Carcinoid Syndrome. ( 29906424 )
2018
10
Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome. ( 29724499 )
2018
11
Telotristat ethyl: a novel agent for the therapy of carcinoid syndrome diarrhea. ( 29350062 )
2018
12
Telotristat Ethyl: A Review in Carcinoid Syndrome Diarrhoea. ( 29931594 )
2018
13
Distinct Imaging Characteristics of Different Metastases From Primary Prostate Adenocarcinoma and Rectal Carcinoid Tumor on 18F-Fluciclovine and 68Ga-DOTATATE PET/CT. ( 30371597 )
2018
14
A Case of Carcinoid Syndrome Due to Malignant Metastatic Carcinoid Tumor with Carcinoid Heart Disease Involving Four Cardiac Valves. ( 29527003 )
2018
15
Grade 3 Neuroendocrine Tumor (G3 NET) in a Background of Multiple Serotonin Cell Neoplasms of the Ileum Associated with Carcinoid Syndrome and Aggressive Behavior. ( 30076568 )
2018
16
Telotristat ethyl for the treatment of carcinoid syndrome diarrhea not controlled by somatostatin analogues. ( 30090879 )
2018
17
Economic analysis of inadequate symptom control in carcinoid syndrome in the United States. ( 30095284 )
2018
18
New Treatments for the Carcinoid Syndrome. ( 30098716 )
2018
19
Carcinoid syndrome: update on the pathophysiology and treatment. ( 30133565 )
2018
20
In Reply: Telotristat Ethyl for Patients With Carcinoid Syndrome Associated With Chest Pain and Hypertension. ( 30153219 )
2018
21
Image Gallery: Flush in carcinoid syndrome. ( 30156289 )
2018
22
Oral Ondansetron Offers Effective Antidiarrheal Activity for Carcinoid Syndrome Refractory to Somatostatin Analogs. ( 30171068 )
2018
23
Patent foramen ovale with an enormous right-to-left shunt: unusual reversible cause of hypoxia in carcinoid syndrome. ( 30184060 )
2018
24
Primary Mesenteric Carcinoid Tumor Presenting with Carcinoid Syndrome. ( 30186091 )
2018
25
Cases in a series of carcinoid syndrome and carcinoid heart disease. ( 30204224 )
2018
26
An update of lanreotide acetate for treatment of adults with carcinoid syndrome. ( 30209440 )
2018
27
Intraoperative carcinoid syndrome during small-bowel neuroendocrine tumour surgery. ( 30352418 )
2018
28
Influence of carcinoid syndrome on the clinical characteristics and outcomes of patients with gastroenteropancreatic neuroendocrine tumors undergoing operative resection. ( 30377003 )
2018
29
Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study. ( 30449217 )
2018
30
Impact of carcinoid syndrome symptoms and long-term use of somatostatin analogs on quality of life in patients with carcinoid syndrome: A survey study. ( 30461659 )
2018
31
Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR. ( 30477789 )
2018
32
Resection of a mature cystic teratoma of the liver harboring a carcinoid tumor. ( 30397434 )
2018
33
Unusual cardiac paraganglioma mimicking an atypical carcinoid tumor of the lung. ( 29600100 )
2018
34
Metastatic medullary thyroid carcinoma or calcitonin-secreting carcinoid tumor of lung? A diagnostic dilemma in a patient with lung mass and thyroid nodule. ( 29124912 )
2018
35
Case report: Ectopic Cushing's syndrome in a young male with hidden lung carcinoid tumor. ( 29202350 )
2018
36
Primary Pulmonary Carcinoid Tumor: A Long-term Single Institution Experience. ( 26270444 )
2018
37
Rectal Carcinoid Tumor With Liver Metastases Treated by Local Excision and Orthotopic Liver Transplant With Long-term Follow-up. ( 28350289 )
2018
38
Kidney carcinoid tumor: Histological, immunohistochemical and ultrastructural features. ( 29192809 )
2018
39
Clinicopathological indicators of survival among patients with pulmonary carcinoid tumor. ( 29463166 )
2018
40
Subcutaneous metastasis of a pulmonary carcinoid tumor: A case report. ( 29480829 )
2018
41
Endobronchial Tuberculosis Simulating Carcinoid Tumor. ( 29482702 )
2018
42
Successful Salvage Chemotherapy with Streptozocin in a Patient with Mediastinal Atypical Carcinoid Tumor Who Had Relapsed after Various Prior Therapies. ( 29515410 )
2018
43
Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [18F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation. ( 29541580 )
2018
44
Endobronchial carcinoid tumor: Radiological findings of a clinical case. ( 29561937 )
2018
45
Posterior fossa metastasis of lung carcinoid tumor: case report. ( 29607688 )
2018
46
Antidepressants appear safe in patients with carcinoid tumor: Results of a retrospective review. ( 29622373 )
2018
47
Significance of cytodiagnosis in primary carcinoid tumor of the middle ear: A case report. ( 29731914 )
2018
48
Assessment of the prognostic factors in patients with pulmonary carcinoid tumor: a population-based study. ( 29733505 )
2018
49
Corrigendum to "Antidepressants appear safe in patients with carcinoid tumor: Results of a retrospective review" [YEJSO 44 (6) (June 2018) 744-749]. ( 29934054 )
2018
50
Catatonia as a presenting symptom of ectopic adrenocorticotropic hormone syndrome caused by thymic carcinoid tumor. ( 29968699 )
2018

Variations for Carcinoid Syndrome

Expression for Carcinoid Syndrome

Search GEO for disease gene expression data for Carcinoid Syndrome.

Pathways for Carcinoid Syndrome

Pathways related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.99 CALCA ENO2 NPY SYP
2 11.71 HTR3A SST VEGFA
3 11.13 ENO2 IGF1 VEGFA
4 10.7 IGF1 SYP VEGFA
5 10.62 NPY PYY

GO Terms for Carcinoid Syndrome

Cellular components related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 CALCA CHGA GHRH IFNA2 IGF1 NPY
2 neuron projection GO:0043005 9.62 CALCA GHRH HTR3A SYP
3 neuronal cell body GO:0043025 9.56 CALCA ENO2 HTR3A SST
4 terminal bouton GO:0043195 9.33 CALCA GHRH SYP
5 extracellular space GO:0005615 9.32 CALCA CHGA ENO2 GHRH IFNA2 IGF1

Biological processes related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.88 CALCA GHRH NPY NTS PYY SST
2 cell-cell signaling GO:0007267 9.62 CALCA GHRH IFNA2 SST
3 neuropeptide signaling pathway GO:0007218 9.61 CALCA NPY PYY
4 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.54 IFNA2 IGF1 VEGFA
5 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.46 GHRH IGF1
6 regulation of blood pressure GO:0008217 9.43 CALCA CHGA NPY
7 response to heat GO:0009408 9.33 CALCA IGF1 SST
8 regulation of signaling receptor activity GO:0010469 9.28 CALCA GHRH IFNA2 IGF1 NPY NTS
9 feeding behavior GO:0007631 9.13 CALCA NPY PYY

Molecular functions related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 9.26 GHRH NPY NTS PYY
2 hormone activity GO:0005179 9.1 CALCA GHRH IGF1 NPY PYY SST

Sources for Carcinoid Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....